Hormone therapy for preventing cardiovascular disease in post-menopausal women.

@article{Boardman2015HormoneTF,
  title={Hormone therapy for preventing cardiovascular disease in post-menopausal women.},
  author={Henry Boardman and Louise Charlotte Hartley and Anne Eisinga and Caroline Main and Marta Roqu{\'e} i Figuls and Xavier Bonfill Cosp and Rafael Gabriel S{\'a}nchez and Beatrice Knight},
  journal={The Cochrane database of systematic reviews},
  year={2015},
  volume={3},
  pages={
          CD002229
        }
}
BACKGROUND Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. [...] Key MethodSEARCH METHODS We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE and LILACS.Expand
Cochrane corner: oral hormone therapy and cardiovascular outcomes in post-menopausal women
TLDR
This subgroup analysis demonstrated there was a trend to reduced likelihood of cardiovascular outcomes in women who started HT before the age of 60, and suggested that associations between oral HT and cardiovascular outcomes are not uniform across all age groups.
Long-term hormone therapy for perimenopausal and postmenopausal women.
TLDR
Assessment of effects of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment found use of combined continuous HT significantly increased the risk of venous thromboembolism.
Cardiovascular benefits of HRT may differ by patient age
TLDR
A meta-analysis of randomised controlled trials comparing oral ERT/HRT with either a placebo or a no-treatment control for 6 months or longer found those women with the evidence of being menopausal either with or without evidence of existing CVD to have a negative risk/benefit balance.
The Role of Menopausal Hormone Therapy in Reducing All-cause Mortality in Postmenopausal Women Younger than 60 Years: An Adaptive Meta-analysis
TLDR
A scientific and valid position is proposed for the conflicting recommendations of the CDSR (2015) and the USPSTF (2017) on MHT to rearrange and update the selected articles to include newer publications, and to conduct subgroup analyses by MHT regimen.
Long-term menopausal hormone therapy and health consequences – how to choose sides?
  • A. Pines, S. Shapiro
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2015
TLDR
Many large, observational studies such as a recent one from Finland (3.3 million years of HT exposure) have shown that the risk of CHD or stroke death and all-cause mortality was significantly reduced, both in those who initiated HT below or above age 60 years.
Menopausal Hormone Therapy: a Comprehensive Review
TLDR
Healthcare providers need to be aware of the current options for MHT, current indications, contraindications, long-term ASCVD risks, and nonhormonal options for high-risk women.
A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases
TLDR
Differential clinical effects depending on timing of initiation, underlying disease, regimen type, and route of administration were identified through subgroup analyses, suggesting that underlying disease and timing of initiated therapy in postmenopausal women should be carefully considered.
Sex hormone therapy and progression of cardiovascular disease in menopausal women.
TLDR
As medicine enters an era of personalization of treatment options, additional research into sex differences in the aetiology of CV diseases will lead to better risk identification for CV disease in women and identify whether a woman might receive CV benefit from specific formulations and doses of MHT.
Clinical trials in menopause
TLDR
The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women and new directions specifically related to menopausal hormone therapy (HT) and vascular disease risk are highlighted.
Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis.
TLDR
The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer, whereas estrogen use was not associated with mortality of other types of cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 233 REFERENCES
Hormone therapy for preventing cardiovascular disease in post-menopausal women.
TLDR
Treatment with HT in post-menopausal women for either primary or secondary prevention of CVD events is not effective, and causes an increase in the risk of stroke, and venous thromboembolic events.
Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women.
TLDR
No protective effect of HRT was seen for any of the cardiovascular outcomes assessed and a recommendation for initiating HRT for the reason of preventing cardiovascular events in post-menopausal women should not be made.
Hormone therapy and cardiovascular disease: a systematic review and meta-analysis.
TLDR
This systematic review, incorporating the latest available trial data, shows that hormone therapy does not significantly change the risk of all-cause morality, CHD death or non-fatal AMI but increases therisk of stroke in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial
TLDR
Oestradiol valerate does not reduce the overall risk of further cardiac events in postmenopausal women who have survived a myocardial infarction, and all-cause mortality was not significant.
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
TLDR
Whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began is explored to explore and women who initiated hormone therapy closer toMenopause tended to have reduced CHD risk compared with the increase inCHD risk among women more distant from menopausal symptoms.
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial
TLDR
After 10 years of randomised treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke.
The ERA trial: findings and implications for the future
TLDR
R randomized clinical trials were needed to further clarify the role of postmenopausal estrogen replacement in the prevention of heart disease and various theories emerged as researchers attempted to understand the HERS findings.
A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease
TLDR
The relation among low-dose estrogen, short-term hormone use, and cardiovascular events in 70 533 postmenopausal women with no previous cardiovascular disease who were followed for up to 20 years is examined.
The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial
TLDR
The trial was prematurely closed during recruitment following publication of early results from the Women's Health Initiative, and the WISDOM experience leads to some simple messages that funders and investigators should make every effort to develop international collaboration with joint funding.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
TLDR
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
...
1
2
3
4
5
...